The shift towards digital technologies has been accelerated by the ongoing COVID-19 pandemic, which has forced a number of industries to operate remotely, including the pharmaceutical industry.
GlobalData has conducted a survey to assess the obstacles to successful digital transformation in pharmaceutical companies.
Obstacles to Digital Transformation
Lack of specific skills and talents was the biggest hurdle for digital transformation as opined by 46% of the survey respondents, followed by organisational silos as opined by 42% of the respondents.
Insufficient funding was voted as the third major obstacle in digital transformation by 40% of the respondents, followed by legacy systems and risk-averse culture by 37% and 35% of the respondents, respectively.
Competing priorities of senior executives and regulation and compliance challenges were each voted by 29% of the respondents as the major obstacles, followed by cyber security and privacy requirements (20%) and IT and business misalignment (20%).
Conflicting corporate strategies was voted as a major obstacle for digital transformation by 17% of the respondents.
The analysis is based on 156 responses received from the Digital Platform and Emerging Technology Survey in Health Care Industry, conducted between 17 September and 06 October 2020.
